897 related articles for article (PubMed ID: 29939893)
41. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
42. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists.
Shakespeare TP
Radiat Oncol; 2015 Nov; 10():233. PubMed ID: 26582424
[TBL] [Abstract][Full Text] [Related]
43. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
44. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
[TBL] [Abstract][Full Text] [Related]
45.
Werner RA; Derlin T; Lapa C; Sheikbahaei S; Higuchi T; Giesel FL; Behr S; Drzezga A; Kimura H; Buck AK; Bengel FM; Pomper MG; Gorin MA; Rowe SP
Theranostics; 2020; 10(1):1-16. PubMed ID: 31903102
[TBL] [Abstract][Full Text] [Related]
46. Imaging of Prostate Cancer Using
Singh A; Kulkarni HR; Baum RP
PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
[TBL] [Abstract][Full Text] [Related]
47. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
Rai BP; Baum RP; Patel A; Hughes R; Alonzi R; Lane T; Adshead J; Vasdev N
Urology; 2016 Sep; 95():11-5. PubMed ID: 26790588
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo comparative study of a novel
Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
[No Abstract] [Full Text] [Related]
49. [The role of PSMA PET-CT in patients with metastatic prostate cancer].
von Hardenberg J; Büsing KA; Nuhn P; Ritter M
Urologe A; 2017 Nov; 56(11):1410-1416. PubMed ID: 28980045
[TBL] [Abstract][Full Text] [Related]
50. Rapidly changing landscape of PET/CT imaging in prostate cancer.
Morigi JJ; Fanti S; Murphy D; Hofman MS
Curr Opin Urol; 2016 Sep; 26(5):493-500. PubMed ID: 27467137
[TBL] [Abstract][Full Text] [Related]
51. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
52. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
53. Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen.
Kuppermann D; Calais J; Marks LS
J Urol; 2022 Apr; 207(4):769-778. PubMed ID: 35085002
[TBL] [Abstract][Full Text] [Related]
54. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
55. PET/CT imaging of prostate cancer in the era of small molecule prostate specific membrane antigen targeted tracers.
Vrachimis A; Ferentinos K; Demetriou E; Ioannides C; Zamboglou N
Hell J Nucl Med; 2020; 23(3):339-345. PubMed ID: 33306762
[TBL] [Abstract][Full Text] [Related]
56. Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature.
Ekmekcioglu Ö; Busstra M; Klass ND; Verzijlbergen F
J Nucl Med; 2019 Oct; 60(10):1394-1398. PubMed ID: 30850500
[No Abstract] [Full Text] [Related]
57. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer.
Maurer T; Schwamborn K; Schottelius M; Wester HJ; Schwaiger M; Gschwend JE; Eiber M
Clin Genitourin Cancer; 2016 Oct; 14(5):e549-e552. PubMed ID: 27318956
[No Abstract] [Full Text] [Related]
58. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
Al-Bayati M; Grueneisen J; Lütje S; Sawicki LM; Suntharalingam S; Tschirdewahn S; Forsting M; Rübben H; Herrmann K; Umutlu L; Wetter A
Urol Int; 2018; 100(2):164-171. PubMed ID: 29393268
[TBL] [Abstract][Full Text] [Related]
59. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
[TBL] [Abstract][Full Text] [Related]
60. Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?
Vetrone L; Fortunati E; Castellucci P; Fanti S
Semin Nucl Med; 2024 Jan; 54(1):150-162. PubMed ID: 37394289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
